Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exagamglogene autotemcel - CRISPR Therapeutics/Vertex Pharmaceuticals

Next Previous
Drug Profile

Exagamglogene autotemcel - CRISPR Therapeutics/Vertex Pharmaceuticals

Alternative Names: Autologous CRISPR-Cas9 modified CD34+ hHSPCs - CRISPR Therapeutics/Vertex Pharmaceuticals; Autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells - CRISPR Therapeutics/Vertex Pharmaceuticals; CASGEVY; CRISPR/Cas9 gene-edited therapy - CRISPR Therapeutics/Vertex Pharmaceuticals; CTX-001; Exa-cel

Latest Information Update: 20 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CRISPR Therapeutics
  • Developer CRISPR Therapeutics; Vertex Pharmaceuticals
  • Class Gene therapies; Haematopoietic stem cells therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Fetal haemoglobin expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia; Beta-thalassaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Beta-thalassaemia; Sickle cell anaemia

Most Recent Events

  • 31 Dec 2024 Registered for Beta-thalassaemia in United Arab Emirates (IV)
  • 31 Dec 2024 Registered for Sickle cell anaemia in United Arab Emirates (IV)
  • 08 Dec 2024 Vertex Pharmaceuticals plans to file regulatory submissions in the United Arab Emirates and Kuwait

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top